SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck5/12/2017 11:59:02 AM
   of 3661
 
Ardelyx (ARDX) off 35% or so on superficially successful P3 trial in IBS-C. They missed a secondary endpoint that was part of the primary endpoint while hitting the primary, anyway. Further, on longer time frames, treatment effect diminished much less than placebo, and so the drug was stat sig on all of those endpoints. Given that the next trial to read out is on longer time frames, ARDX my be worth a look. I don't know the competition in this space well, so I'm not saying hit the buy button right away, but this could well be worth some DD (I'm traveling a lot in coming weeks, and won't get to it until mid June, at best).

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News